News | January 23, 2026
EMA hits record high in vet medicine nods for second year running
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated
